About Sebastian Unizony, MD

Dr Unizony is the director of the Rheumatology Vasculitis Program. His main academic interests include the use of clinical and translational research methods to advance the treatment for patients with systemic vasculitides and related disorders, including giant cell arteritis, polymyalgia rheumatica and ANCA-associated vasculitis. He is a member of the Pan American League of Associations for Rheumatology (PANLAR) vasculitis group that has published treatment guidelines for giant cell arteritis, Takayasu’s arteritis and ANCA-associated vasculitis. A list of his publications can be found in the following link:

https://pubmed.ncbi.nlm.nih.gov/?term=Unizony+S&sort=date

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Languages:

Locations

Mass General Rheumatology
55 Fruit St.
Yawkey Center for Outpatient Care
Suite 4B
Boston, MA 02114
Phone: 617-726-7938

Medical Education

  • MD, Universidad Nacional de La Plata
  • Residency, Hospital Carlos Durand
  • Residency, St. Luke's Roosevelt Hospital Center
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Rheumatology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Publications

  • Matza MA, Arevalo AB, Unizony S. Imaging Challenges and Developments in Large-vessel Vasculitis. Rheum Dis Clin North Am. 2024, PMID: 39415370

    Magri SJ, Ugarte-Gil MF, Brance ML, Flores-Su?rez LF, Fern?ndez-?vila DG, Scolnik M, Sato EI, de Souza AWS, Saldarriaga-Rivera LM, Babini AM, Zamora NV, Felquer MLA, Vergara F, Carlevaris L, Scarafia S, Guppy ERS, Unizony S; Pan American League of Associations for Rheumatology. Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis. Lancet Rheumatol. 2023 PMID: 38251580

    Unizony S, Matza MA, Jarvie A, O'Dea D, Fernandes AD, Stone JH. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2023, PMID: 38251564

    Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos GD, Marrache F, Patel N, Dasgupta B; SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023, PMID: 37792612 Clinical Trial.

    Matza MA, Dagincourt N, Mohan SV, Pavlov A, Han J, Stone JH, Unizony S. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. RMD Open. 2023, PMID: 37024237

    Scolnik M, Brance ML, Fern?ndez-?vila DG, Inoue Sato E, de Souza AWS, Magri SJ, Saldarriaga-Rivera LM, Ugarte-Gil MF, Flores-Suarez LF, Babini A, Zamora NV, Acosta Felquer ML, Vergara F, Carlevaris L, Scarafia S, Soriano Guppy ER, Unizony S; Pan American League of Associations for Rheumatology (PANLAR). Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis. Lancet Rheumatol. 2022, PMID: 38261393

    Cid MC*, Unizony S*, Blockmans D, Brouwer E, Dagna L, Dasgupta B, Hellmich B, Molloy E, Salvarani C, Trapnell BC, Warrington KJ, Wicks I, Samant M, Zhou T, Pupim L, Paolini JF; KPL-301-C001 Investigators. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022, PMID: 35264321. * Co-first authors

    Unizony S, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021, PMID: 34049857

    Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony S, Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017, PMID: 28745999

Reviews: Comments and Ratings